ReviewBiochimica et biophysica acta2009
Translocations in epithelial cancers.
Review in Biochimica et biophysica acta, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Latest developments in the pathobiology of Ewing sarcoma.Journal of bone oncology · 2022Review
- Overview of research on fusion genes in prostate cancer.Translational cancer research · 2020Review
- m1A Regulated Genes Modulate PI3K/AKT/mTOR and ErbB Pathways in Gastrointestinal Cancer.Translational oncology · 2019Article
- Recurrent rearrangements of the Myb/SANT-like DNA-binding domain containing 3 gene (MSANTD3) in salivary gland acinic cell carcinoma.PloS one · 2017Article
- Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine.BioMed research international · 2016Review
- Hypothesis: Artifacts, Including Spurious Chimeric RNAs with a Short Homologous Sequence, Caused by Consecutive Reverse Transcriptions and Endogenous Random Primers.Journal of Cancer · 2015Review
- Review
- Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.Neoplasia (New York, N.Y.) · 2013Article
- Chromosomal translocations among the healthy human population: implications in oncogenesis.Cellular and molecular life sciences : CMLS · 2013Review
- Molecular heterogeneity in mucoepidermoid carcinoma: conceptual and practical implications.Head and neck pathology · 2013Review
- PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.Cancer research · 2012Article
- Salivary gland cancers: biology and molecular targets for therapy.Current oncology reports · 2012Article
- Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.Disease models & mechanisms · 2012Article
- Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
- Perturbation of BRD4 protein function by BRD4-NUT protein abrogates cellular differentiation in NUT midline carcinoma.The Journal of biological chemistry · 2011Article
- How does DNA break during chromosomal translocations?Nucleic acids research · 2011Review
- Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.Cancer cell · 2011Article
- Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance.Clinical cancer research : an official journal of the American Association for Cancer Research · 2010Article
- Histological types of breast cancer: how special are they?Molecular oncology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Genomic translocations leading to the expression of chimeric transcripts characterize several hematologic, mesenchymal and epithelial malignancies. While several gene fusions have been linked to essential molecular events in hematologic malignancies, the identification and characterization of recurrent chimeric transcripts in epithelial cancers has been limited. However, the recent discovery of the recurrent gene fusions in prostate cancer has sparked a revitalization of the quest to identify novel rearrangements in epithelial malignancies. Here, the molecular mechanisms of gene fusions that drive several epithelial cancers and the recent technological advances that increase the speed and reliability of recurrent gene fusion discovery are explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.